Table 3.
Age (mean, range) | 58.4 (5–96) | |
Gender | Female | 47.6% |
Male | 52.4% | |
IPI | 0–1 | 41.8% |
2 | 27.1% | |
3 | 17.1% | |
4–5 | 14.1% | |
Follow-up (median) | 60.9 | |
Overall survival | 5-year cumulative survival | 59.8% |
Failure | Cured versus fatal/refractory disease | 50.6%/49.4% |
Failure-free survival | 5-year cumulative survival | 50.4% |